

USE OF GLP1-AGONISTS IN THE TREATMENT OF PATIENTS WITH TYPE I DIABETES

ABSTRACT OF THE DISCLOSURE

The present invention relates to the use of GLP-1 agonists in the treatment of patients with type I diabetes, where the patient is newly diagnosed with type I diabetes when treatment with the GLP-1 agonist is initiated. The present invention also relates to the use of GLP-1 agonists to prolong the remission period in such patients. The present invention further relates to a diagnostic test which utilizes measurement of endogenous GLP-1 levels to predict loss of beta cell function in patients with type I diabetes. The present invention further relates to methods for determining whether a patient with type I diabetes is in need of treatment with a GLP-1 agonist and/or is in remission.